BrainCheck, a Houston, TX-based cognitive healthcare platform for physicians, raised $10m in Series B funding.
The round, which brought the total capital raised to date to $20m, was led by Next Coast Ventures and S3 Ventures, with participation from Nueterra Capital, Tensility Ventures, and True Wealth Ventures. In addition, UPMC Enterprises and SelectQuote (NYSE: SLQT) have joined as strategic investors.
The company intends to use the funds to accelerate the adoption of its platform.
Led by Yael Katz, PhD, co-founder and CEO, BrainCheck is an FDA Class II Software as a Medical Device (SaMD), which allows physicians to facilitate in-person or remote assessment for early and accurate impressions of cognitive function. The 10-to-15-minute test is covered by Medicare and by most private insurers. BrainCheck can be administered on an iPhone, iPad or desktop computer to evaluate a patient, assign them a Cognitive Quotient (CQ) score, and produce a personalized cognitive care plan within minutes.
The platform is used in over 400 neurology, primary care and geriatrics practices to reduce the human and economic toll of cognitive impairment and dementia.